Gentile D M, Verhoeven C H, Shimada T, Back D J
Department of Pharmacology and Therapeutics, New Medical Building, Liverpool, L69 3GE, United Kingdom.
J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
Desogestrel is a 3-deoxo progestogenic steroid that requires bioactivation to 3-ketodesogestrel. In these studies we have attempted to define the pathway of 3-ketodesogestrel formation and characterise the enzymes responsible for this biotransformation in vitro. Initial studies using deuterated desogestrel confirmed that desogestrel is metabolised by human liver microsomes via 3alpha-hydroxy and 3beta-hydroxydesogestrel to 3-ketodesogestrel. Metabolites were analysed by radiometric high-performance liquid chromatography and were identified by liquid chromatography-mass spectrometry and by cochromatography with authentic standards. Desogestrel was metabolised by microsomes from lymphoblasts containing cDNA-expressed CYP2C9 and CYP2C19 to 3alpha-hydroxydesogestrel with small amounts of 3beta-hydroxydesogestrel also being observed. The Km value for 3alpha-hydroxylation by CYP2C9 cell line microsomes was 6.5 microM and the corresponding Vmax value was 1269 pmole. mg-1. min-1. Sulfaphenazole potently inhibited 3alpha-hydroxydesogestrel formation by CYP2C9 microsomes with a Ki value of 0.91 microM. There was a significant negative correlation between 3-ketodesogestrel and CYP3A4 content/activity in a panel of human livers suggesting that the further metabolism of 3-ketodesogestrel is mediated by CYP3A4. Sulfaphenazole partially inhibited 3alpha-hydroxydesogestrel and 3-ketodesogestrel formation in human liver microsomes indicating a possible in vivo role for CYP2C9. In addition, when sulfaphenazole was combined with S-mephenytoin, further inhibition of 3alpha-hydroxydesogestrel formation was observed suggesting a possible role for CYP2C19. This was confirmed in incubations with inhibitory antibodies. Whereas an anti-CYP2C9/2C19 antibody completely abolished desogestrel metabolism, anti-CYP3A4 and anti-CYP2E1 were not inhibitory. We conclude that CYP2C9 and possibly CYP2C19 and important isoforms catalysing the initial hydroxylation of desogestrel.
去氧孕烯是一种3-脱氧孕甾类化合物,需要生物活化形成3-酮基去氧孕烯。在这些研究中,我们试图确定3-酮基去氧孕烯的形成途径,并在体外表征负责这种生物转化的酶。使用氘代去氧孕烯的初步研究证实,去氧孕烯在人肝微粒体中通过3α-羟基和3β-羟基去氧孕烯代谢为3-酮基去氧孕烯。代谢产物通过放射性高效液相色谱法进行分析,并通过液相色谱-质谱法以及与标准品共色谱法进行鉴定。去氧孕烯被含有cDNA表达的CYP2C9和CYP2C19的淋巴母细胞微粒体代谢为3α-羟基去氧孕烯,同时也观察到少量的3β-羟基去氧孕烯。CYP2C9细胞系微粒体对3α-羟基化的Km值为6.5微摩尔,相应的Vmax值为1269皮摩尔·毫克-1·分钟-1。磺胺苯吡唑强烈抑制CYP2C9微粒体形成3α-羟基去氧孕烯,Ki值为0.91微摩尔。在一组人肝脏中,3-酮基去氧孕烯与CYP3A4含量/活性之间存在显著负相关,这表明3-酮基去氧孕烯的进一步代谢由CYP3A4介导。磺胺苯吡唑部分抑制人肝微粒体中3α-羟基去氧孕烯和3-酮基去氧孕烯的形成,表明CYP2C9在体内可能发挥作用。此外,当磺胺苯吡唑与S-美芬妥因联合使用时,观察到对3α-羟基去氧孕烯形成的进一步抑制,这表明CYP2C19可能发挥作用。这在与抑制性抗体的孵育中得到证实。抗CYP2C9/2C19抗体完全消除了去氧孕烯的代谢,而抗CYP3A4和抗CYP2E1则没有抑制作用。我们得出结论,CYP2C9以及可能的CYP2C19是催化去氧孕烯初始羟基化的重要同工酶。